NCT03443843View on ClinicalTrials.gov

A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure

PHASE4CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

February 21, 2018

Primary Completion Date

May 11, 2018

Study Completion Date

May 11, 2018

Conditions
Rhinitis, Allergic
Interventions
DRUG

loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D)

Single dose of Loratadine/pseudoephedrine in tablet 5 mg/120 mg orally

DRUG

Placebo tablet

Placebo tablet orally

DRUG

Fluticasone Propionate

Fluticasone Propionate Nasal Spray 50mcg per spray, 2 sprays per nostril

DRUG

Placebo spray

Placebo Nasal Spray, 2 sprays per nostril

Trial Locations (1)

K7L 2V7

Kingston General Hospital, Kingston

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT03443843 - A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure | Biotech Hunter | Biotech Hunter